KYMCO
16.11.2023 11:27:28 CET | Business Wire | Press release
Building on the pinnacle of over 25 years of EV innovation, KYMCO announced three ground-breaking technologies to accelerate the mass-adoption of electric motorcycles: The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators. "Today, we stand on the brink of a remarkable transformation in the world of mobility. A shift that reshapes the way we move, a change that KYMCO leads," said Allen Ko, Chairman of KYMCO.
KYMCO's Vision: A World with Electric Motorcycles Everywhere
KYMCO sees Energy Companies provide riders with battery services for electric motorcycles. With this battery service, the riders receive batteries from energy companies with guaranteed performance and pay only for actual battery usage. Riders no longer need to buy batteries when purchasing their vehicle.
KYMCO sees EV Manufacturers introduce electric motorcycles with integrated onboard battery metering. Every electric motorcycle works with the Energy Companies' battery service. Without the costs of the batteries, electric motorcycles are more affordable than ever before.
KYMCO sees Battery-swapping Network Operators deploying thousands of battery-swapping stations, forever erasing range anxiety. Battery-swapping networks provide riders with zero-wait charging and unlimited range.
More profoundly, KYMCO sees riders choosing from a wide variety of electric motorcycles made by various manufacturers and battery service plans that best match their lifestyles. For energy replenishment, riders charge their vehicle in the garage or charge their battery in the house. In the city, riders swap on the go at the nearest battery-swapping station. And while traveling, riders get unlimited range from the extensive battery-swapping network to power all their journeys.
Ionex EV Solution: The True Arrival of the Electric Era
To address all current challenges and future ambitions to fulfill KYMCO's vision, Chairman Ko announced three ground-breaking technologies to propel all stakeholders to collaborate as the Ionex Open Consortium, an EV ecosystem that brings affordable, convenient, and sustainable electric mobility to all, the true arrival of the electric era.
The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators make up the revolutionary Ionex EV Solution. The Ionex EV Solution aims to benefit every stakeholder in electric mobility, especially all consumers, businesses, and governments wishing to go electric.
"We look forward to seeing the impact the Ionex EV Solution will have on Southeast Asia's fast-developing EV ecosystem. We see its potential to bring about more affordable and convenient electric mobility," expressed Chuck Kim, Managing Director of Group Business Development and Capital Markets, Grab.
"Right here, right now, marks the inflection point of the electric era," said Allen Ko. "KYMCO's game-changing Ionex EV Solution is paving the way for all stakeholders to jointly transition to the electric future. I invite everyone to join us on this transformative journey."
About KYMCO
KYMCO is a brand with a rich history spanning nearly 60 years in the powersport industry. They focus on innovation, quality, style and have established themselves as a leading manufacturer of scooters, motorcycles, and ATVs worldwide. Their state-of-the-art manufacturing facilities and use of the latest technologies ensure that every vehicle they produce is reliable and stylish.
KYMCO is committed to reducing the environmental footprint, promoting sustainability, supporting social causes, and giving back to the communities. Whether riders seek a sleek and sporty scooter or a rugged and durable ATV, KYMCO has something for everyone. KYMCO is a brand that embodies the best of what the powersport industry offers - innovation, quality, style, and a commitment to making the world a better place.
You can learn more about KYMCO at www.kymco.com
Learn more about Ionex at www.ionexenergy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231115883583/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom